Journal of Clinical and Aesthetic Dermatology

FEB 2018

An evidence-based, peer-reviewed journal for practicing clinicians in the field of dermatology

Issue link: http://jcadonline.epubxp.com/i/934167

Contents of this Issue

Navigation

Page 5 of 62

INDICATIONS Otezla® (apremilast) is indicated for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Otezla is indicated for the treatment of adult patients with active psoriatic arthritis. IMPORTANT SAFETY INFORMATION Contraindications Otezla® (apremilast) is contraindicated in patients with a known hypersensitivity to apremilast or to any of the excipients in the formulation. Please see additional Important Safety Information and Brief Summary of Full Prescribing Information on the following pages. Contact your Otezla representative to learn about other prescription benefit plans that no longer require biologic agent step-edits for Otezla For patients with commercial insurance, * SafeGuardRx SM Program has 1 biologic step for patients with a diagnosis of psoriatic arthritis only. Plan Plaque Psoriasis Psoriatic Arthritis Aetna Prescription Drug Benefit Cigna Prescription Drug List Express Scripts National Preferred Formulary* Y our patients on commercial insurance can now access Otezla without any biologic step-edit requirements on: Getting Otezla® (apremilast) JUST GOT EASIER Contact your Otezla representative to learn about biologic agent step-edits for Otezla

Articles in this issue

Links on this page

Archives of this issue

view archives of Journal of Clinical and Aesthetic Dermatology - FEB 2018